Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With RAS (KRAS, NRAS) Wild-type, Unresectable, Advanced/Recurrent Colorectal Cancer

NCT02613221 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02613221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02613221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With RAS (KRAS, NRAS) Wild-type, Unresectable, Advanced/Recurrent Colorectal Cancer
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Completed
Start date
December 7, 2015
Completion date
March 30, 2018
Enrollment
56 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer